InVivo Therapeutics Holdings Corp (NVIVQ)

[Devo33]

I will try, just for the sake of discussion and gaining insight from others.

1. Too soon. Still in the development, phase which does not effect the balance sheet at this time but gives insight as to how it will in the future. The process of proving the efficacy and safety of the NSS has gone well. The FDA mandate OPC has essentially been met. The process of presenting the surgical process and results to the professional communities in an effort to have them be accepted as the best and standard treatment for acute thoracic spinal cord injury is underway.

2. They don't need to. Their employment packages give them generous amounts of warrants. As the future becomes clearer they may. Again ...too soon.

3. No rate increase in December. Again...too soon. Interest rate increases will be implemented to control economic growth. The Trump agenda has not been delineated sufficiently yet. There will need to be executive and legislative action first and some measured results before the assessment that increasing interest rates are necessary.